Build status - In Progress

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
Recruiting
1 years - 100 years
All
Phase 3
1 Location

Brief description of study

    The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

    Eligibility of study

    You may be eligible for this study if you meet the following criteria:

    • Conditions: IgAN,primary immunoglobulin A nephropathy
    • Age: 1 years - 100 years
    • Gender: All


    Updated on 04 Aug 2024. Study ID: 833614

    Find a site

    We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
    Would you like to be notified about other trials? Sign up for Patient Notification Services.
    Sign up

    Send a message

    Enter your contact details to connect with study team

    Email

    View email

    Phone

    Phone country flag

    View phone
    Investigator Avatar

    Primary Contact

    First name*
    Last name*
    Email*
    Phone number*
    Preferred way of contact
    Race
    Ethnicity
    Other language

    Interested in the study

    Select a study center that’s convenient for you, and get in touch with the study team.

    Contact a study center